| Autor: |
Booth L; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Roberts JL; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Tavallai M; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Webb T; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Leon D; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Chen J; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., McGuire WP; Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA., Poklepovic A; Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA., Dent P; Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA. |
| Abstrakt: |
We generated afatinib resistant clones of H1975 lung cancer cells by transient exposure of established tumors to the drug and collected the re-grown tumors. Afatinib resistant H1975 clones did not exhibit any additional mutations in proto-oncogenes when compared to control clones. Afatinib resistant H1975 tumor clones expressed less PTEN than control clones and in afatinib resistant clones this correlated with increased basal SRC Y416, ERBB3 Y1289, AKT T308 and mTOR S2448 phosphorylation, decreased expression of ERBB1, ERBB2 and ERBB3 and increased total expression of c-MET, c-KIT and PDGFRβ. Afatinib resistant clones were selectively killed by knock down of [ERBB3 + c-MET + c-KIT] but not by the individual or doublet knock down combinations. The combination of the ERBB1/2/4 inhibitor afatinib with the SRC family inhibitor dasatinib killed afatinib resistant H1975 cells in a greater than additive fashion; other drugs used in combination with dasatinib such as sunitinib, crizotinib and amufatinib were less effective. [Afatinib + dasatinib] treatment profoundly inactivated ERBB3, AKT and mTOR in the H1975 afatinib resistant clones and increased ATG13 S318 phosphorylation. Knock down of ATG13, Beclin1 or eIF2α strong suppressed killing by [ERBB3 + c-MET + c-KIT] knock down, but were only modestly protective against [afatinib + dasatinib] lethality. Thus afatinib resistant H1975 NSCLC cells rely on ERBB1- and SRC-dependent hyper-activation of residual ERBB3 and elevated signaling, due to elevated protein expression, from wild type c-MET and c-KIT to remain alive. Inhibition of ERBB3 signaling via both blockade of SRC and ERBB1 results in tumor cell death. |
